Kraig Biocraft Laboratories, Inc., a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber, announced that a provisional patent application, with groundbreaking technology describing a platform for antigen presentation and antibody test kits, has been filed. The patent lists Dr. Malcolm Fraser of Notre Dame, a member of Kraig’s Scientific Advisory Board, and a scientific consultant to Kraig, as the named inventor.
Dr. Malcolm Fraser explains, “The invention describes engineered polymers which incorporate diagnostic antigens. The genetically fused polymers can potentially be fashioned into a number of different diagnostic test platforms including serum (blood), salivary, and urine based diagnostics,” Fraser continued. “The result would be a diagnostic tool which could simultaneously screen for several diseases or for other important parameters.”
That agreement provides for exclusive licensing rights for Kraig-sponsored research, and is the second patent application of 2008 which was made in accordance with Kraig’s sponsored research program at the University of Notre Dame. The patent application is subject to Kraig’s intellectual property agreement with the University.
CEO, Kim Thompson said, “This ground breaking technology advances Kraig into the growing field of human and animal diagnostics. The tremendous potential of genetically fused polymers for diagnostics can not be ignored. Our announcement is a big step toward fulfilling the promise of genetically engineered fibers for diagnostics and human health.”
Let us hear your thoughts below:
